Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 10 unusual trades. Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020.

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share.

10 analysts have shared their evaluations of Moderna (NASDAQ:MRNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

The most recent trading session ended with Moderna (MRNA) standing at $34.71 ... and the technology-dominated Nasdaq saw an increase of 0.31%. The the stock of biotechnology company has risen ...

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 trades. If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock ...

The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for the past year.

Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available ...